Search

Background: Allergic rhinitis (AR) is a major non‐communicable disease that affects the health‐related quality of life (HRQoL) of patients. However, data on HRQoL and symptom control in AR patients with comorbid asthma (AR + asthma) are lacking. Methods: In this multicentre, cross‐sectional study, patients with AR were screened and administered questionnaires of demographic characteristics and health conditions (symptoms/diagnosis of AR and asthma, disease severity level, and allergic conditions). HRQoL was assessed using a modified version of the RHINASTHMA questionnaire (30, 'not at all bothered' ‐ 150 'very much bothered') and symptom control was evaluated by a modified version of the Control of Allergic Rhinitis/Asthma Test (CARAT) (0, 'no control' ‐ 30, 'very high control'). Results: Out of 643 patients with AR, 500 (78%) had asthma as a comorbidity, and 54% had moderate‐severe intermittent AR, followed by moderate‐severe persistent AR (34%). Compared to the patients with AR alone, patients with AR + asthma had significantly higher RHINASTHMA (e.g., median RHINASTHMA‐total score 48.5 vs. 84, respectively) and a significantly lower CARAT score (median CARAT‐total score 23 vs. 16.5, respectively). Upon stratifying asthma based on severity, AR patients with severe persistent asthma had worse HRQoL and control than those with mild persistent asthma. The association was significantly higher among non‐obese participants compared to obese ones, with RHINASTHMA‐upper symptoms score but not with CARAT. Conclusions: Our observation of poorer HRQoL and symptoms control in AR patients with comorbid asthma supports the importance of a comprehensive approach for the management of AR in case of a comorbid allergic condition. [ABSTRACT FROM AUTHOR]

There is increasing evidence that allergic diseases such as allergic rhinitis (AR) and asthma impair the overall quality of life (QOL) of patients and place a great economic burden on both the individual and society as a whole. While conventional measures, such as a medical history and specific allergy tests, give an indication of the patient's disease and its burden, these may not reflect the disease status accurately or in its entirety. The development of disease-specific instruments (questionnaires) for measuring health-related quality of life (HRQOL) of adults and children with AR, asthma, or co-morbid allergic disease, has led to the recognition that these instruments provide a more accurate estimate of the burden of disease, and additionally represent a formal and validated part of the history. Studies employing HRQOL instruments have indicated that these instruments are simple to administer and represent validated and quantifiable methods for taking a simple patient history. Despite some limitations, these instruments are thought to be particularly useful because they (i) provide additional information on various aspects of disease or treatment which are not readily identified by the clinician, (ii) give an insight into the burden and consequences of allergic disease and (iii) describe the relationship between the medical treatment and improvement in HRQOL, which appears to be the motive behind good compliance and patient satisfaction. [ABSTRACT FROM AUTHOR]